Dr. Achim Krauss is CEO and President of AxeroVision, Inc., a GSK spinout company he founded in 2016 to develop next-generation therapeutics for the treatment of dry eye disease, blepharitis and other ophthalmic inflammatory diseases. Previously, he held various leadership positions at GSK, Pfizer and Allergan. Dr. Krauss has a proven track record in ophthalmic drug discovery and development and was a key contributor to the glaucoma drugs Lumigan® and Vyzulta™. His broad experience spans all areas from discovery to regulatory filing, as well as business development and marketing support in ophthalmology. Until recently, he had served in various positions, including President, on the Board of Directors of the Association for Ocular Pharmacology and Therapeutics. Dr. Krauss earned a B.S. in Pharmacy and his Ph.D., graduating Magna cum Laude, from the University of Tübingen, Germany.